Stockreport

Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026 [Yahoo! Finance]

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
PDF Allogene Therapeutics said on March 12, 2026, that its lead program, cemacabtagene ansegedleucel, or cema-cel, remains on track in the pivotal Phase 2 ALPHA3 trial in f [Read more]